Guides
Is Ipamorelin Legal? What the FDA Actually Says in 2026
Ipamorelin has never had an FDA-approved drug application, and today it sits — unwithdrawn — on FDA's active list of compounding substances with significant safety risks. Here's the current status, with the primary sources.
Ipamorelin shows up on Houston “peptide therapy” menus next to sermorelin and CJC-1295, usually pitched as a gentler growth-hormone booster for muscle gain, fat loss, recovery, or sleep. Unlike BPC-157 or sermorelin — the two peptides we’ve already covered in this glossary — ipamorelin’s FDA story isn’t a withdrawn flag or a lapsed approval. It’s a safety-risk listing the agency has never removed.
What it is
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue — it binds the ghrelin receptor (GHS-R1a) on the pituitary gland and triggers a pulse of the body’s own growth hormone. It has no FDA-approved use, under any name, for any condition.
The FDA status, in order
Never approved, by anyone. We checked Drugs@FDA via the openFDA API and DailyMed, the National Library of Medicine’s database of currently labeled drugs: both return zero results for ipamorelin. No manufacturer has ever taken it through FDA review. There is no discontinued approval to point back to, the way sermorelin sellers point to Geref.
September 29, 2023 — added to FDA’s Category 2 list, and never withdrawn. We checked FDA’s page on bulk drug substances that may present significant safety risks directly: ipamorelin acetate is listed there today, under the 503B interim policy. FDA’s stated concern is specific — a published case report of serious adverse events, including death, when ipamorelin was administered intravenously to improve gastric motility, plus the immunogenicity risk that comes with peptide impurities and the unnatural amino acids in its structure. FDA also says explicitly it hasn’t identified safety data for other injectable routes, so it can’t rule out harm there either — which is a different, more active kind of “we don’t know” than a substance nobody has evaluated at all.
This is not the same status as BPC-157. BPC-157 sat in Category 2 too, but its nomination was withdrawn in April 2026 — FDA no longer flags it as an active safety risk (it’s just not approved for compounding either). Ipamorelin has not been withdrawn. As of this writing, it’s a live entry on FDA’s safety-risk list, not a resolved one.
Not on the 503A Bulks List. We checked that list directly: ipamorelin doesn’t appear on it. Section 503A lets a compounding pharmacy use a bulk substance only if it has a USP/NF monograph, is a component of an FDA-approved drug, or is on this list — and ipamorelin qualifies under none of the three.
Not even up for review. FDA’s Pharmacy Compounding Advisory Committee met July 23–24, 2026, to formally consider seven other peptides — BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, and epitalon — for the 503A list. We checked the meeting agenda directly: ipamorelin wasn’t on it. It isn’t moving through any path toward legitimacy right now.
What this means for a clinic menu
A clinic that calls ipamorelin “safe” or “natural” because it “just tells your body to make its own growth hormone” is describing the mechanism, not the regulatory status. FDA’s own safety-risk listing predates most current Houston clinic marketing and hasn’t been lifted. This is one substance where “gray area” undersells it: FDA has affirmatively flagged it and taken no action to un-flag it.
Red flags we check for
Ipamorelin sold alongside “research use only” language, with dosing instructions anyway. The same pattern we see with BPC-157 — a research-grade label paired with an injection schedule a clinic staffer walks the patient through.
No documented patient-specific need. Compounding is meant to serve an individual patient’s documented medical circumstance, not function as a standing wellness product anyone can add to a package.
No named, NPI-verified prescriber behind the offering. If a clinic can’t say who is prescribing ipamorelin and why, the “medical” framing isn’t real.
This is exactly the pattern that has disqualified clinics from this directory: an ipamorelin-centered peptide menu is one of the specific findings behind two Houston-area exclusions we’ve documented, both offering it alongside CJC-1295 as a growth-hormone “stack.”
Browse our verified GLP-1 and peptide clinics in Houston, read what disqualifies a clinic and why, and see our full verification standard.
Sources: U.S. Food and Drug Administration, Drugs@FDA data via the openFDA API (api.fda.gov/drug/drugsfda.json), search for “ipamorelin” — no matching records, retrieved September 23, 2026. National Library of Medicine, DailyMed API (dailymed.nlm.nih.gov), search for “ipamorelin” — zero currently labeled products, retrieved September 23, 2026. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (Category 2 list; ipamorelin acetate listed under the 503B interim policy, added September 29, 2023, not withdrawn), dateModified April 22, 2026, retrieved September 23, 2026. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act” (503A Bulks List; ipamorelin not present), dateModified May 14, 2026, retrieved September 23, 2026. FDA, “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” (agenda substances: BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, epitalon — ipamorelin not on the agenda), retrieved September 23, 2026. Internal audit records, data/excluded.md, two Houston-area clinic exclusions citing ipamorelin offered alongside CJC-1295 as a growth-hormone peptide stack.
This article is independent editorial content, not medical advice. See our medical disclaimer.